- Home
- FE vs ILMN Comparison
FE vs ILMN Comparison
Compare FE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- ILMN
- Stock Information
- Founded
- FE 1996
- ILMN 1998
- Country
- FE United States
- ILMN United States
- Employees
- FE N/A
- ILMN N/A
- Industry
- FE Electric Utilities: Central
- ILMN Medical Specialities
- Sector
- FE Utilities
- ILMN Health Care
- Exchange
- FE Nasdaq
- ILMN Nasdaq
- Market Cap
- FE 24.5B
- ILMN 23.6B
- IPO Year
- FE N/A
- ILMN 2000
- Fundamental
- Price
- FE $39.92
- ILMN $134.95
- Analyst Decision
- FE Buy
- ILMN Buy
- Analyst Count
- FE 12
- ILMN 17
- Target Price
- FE $46.73
- ILMN $163.12
- AVG Volume (30 Days)
- FE 2.7M
- ILMN 2.3M
- Earning Date
- FE 02-06-2025
- ILMN 02-06-2025
- Dividend Yield
- FE 4.26%
- ILMN N/A
- EPS Growth
- FE 69.38
- ILMN N/A
- EPS
- FE 1.55
- ILMN N/A
- Revenue
- FE $13,257,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- FE $13.72
- ILMN N/A
- Revenue Next Year
- FE $4.41
- ILMN $4.05
- P/E Ratio
- FE $25.73
- ILMN N/A
- Revenue Growth
- FE 4.30
- ILMN N/A
- 52 Week Low
- FE $35.41
- ILMN $97.36
- 52 Week High
- FE $44.97
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- FE 39.00
- ILMN 40.07
- Support Level
- FE $38.81
- ILMN $130.31
- Resistance Level
- FE $39.96
- ILMN $137.69
- Average True Range (ATR)
- FE 0.52
- ILMN 5.08
- MACD
- FE -0.00
- ILMN -1.03
- Stochastic Oscillator
- FE 43.50
- ILMN 21.62
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.